$IRWD News
Last published 6d ago
- 6d agoIRWDIRONWOOD PHARMACEUTICALS INC - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoIRWDIronwood Pharmaceuticals to Host Third Quarter 2026 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5, 2026. Individuals
- 3w agoIRWDIronwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive OfficerBusiness Wire– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a
- 2mo agoIRWDIronwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10th at 10:15 a.m. ET. A
- 3mo agoIRWDIronwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter ResultsBusiness Wire– Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase year-over-year; Raises total revenue guidance to $460 - $485 million and adjusted
- 3mo agoIRWDIronwood Pharmaceuticals to Host Second Quarter 2026 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals
- 4mo agoIRWDIronwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting PatientsBusiness Wire– Ironwood Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline to Retire After 30-Year Career Advancing GI Science and Patient Care – – Dr. Silber, a Drug Development Veteran, Will
- 5mo agoIRWDIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of
- 5mo agoIRWDFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)Business Wire– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved prescription therapy for
- 6mo agoIRWDIronwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial GuidanceBusiness Wire– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue of $107 million, GAAP net income of $41
- 6mo agoIRWDIronwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)Business Wire– Surveyed HCPs identified reduction of days on TPN as a top priority – – Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence – – Additional
- 6mo agoIRWDIronwood Pharmaceuticals to Host First Quarter 2026 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026. Individuals interested in
- 6mo agoIRWDIronwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026Business Wire– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) – – Linaclotide data presentations
- 8mo agoIRWDIronwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of
- 8mo agoIRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 OutlookBusiness Wire– LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue
- 8mo agoIRWDIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026.
- 10mo agoIRWDIronwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial GuidanceBusiness Wire- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - - Ended Q4 2025 with greater than $200
- 1y agoIRWDIronwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial GuidanceBusiness Wire– LINZESS® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year – – GAAP net income of $40 million and adjusted EBITDA of
- 1y agoIRWDIronwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial GuidanceBusiness Wire– LINZESS® (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – – Plans to align with FDA on confirmatory Phase 3 trial design in Q4 2025 – – Progressing
- 1y agoIRWDIronwood Pharmaceuticals Reports First Quarter 2025 ResultsBusiness Wire– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line
- 1y agoIRWDIronwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton
- 1y agoIRWDIronwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA GuidanceBusiness Wire– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in
- 1y agoIRWDIronwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral SupportBusiness Wire– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel syndrome with constipation (IBS-C); first completed Phase III
- 1y agoIRWDIronwood Pharmaceuticals Provides Clinical and Regulatory Update on ApraglutideBusiness Wire– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval – – Company has engaged Goldman Sachs & Co. LLC to explore strategic
- 1y agoIRWDIronwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K FilingBusiness WireIronwood Pharmaceuticals, Inc. (the "Company") (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today
- 1y agoIRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial GuidanceBusiness Wire– Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be
- 1y agoIRWDIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025.
- 1y agoIRWDIronwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the FutureBusiness Wire– Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued
- 1y agoIRWDNVOOzempic is in the next round of Medicare drug price negotiations. See the full list of 15 medicationsCNBCThe list includes Novo Nordisk's blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product.
- 1y agoIRWDIronwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at
- 1y agoIRWDIronwood Pharmaceuticals to Participate in the Jefferies London Healthcare ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on
- 2y agoIRWDIronwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoIRWDIronwood Pharmaceuticals Reports Third Quarter 2024 ResultsBusiness Wire– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood
- 2y agoIRWDOnce-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024Business Wire– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events associated with GI tolerability – – Findings reinforce the clinical
- 2y agoIRWDIronwood Pharmaceuticals to Host Third Quarter 2024 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals
- 2y agoIRWDIronwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 p.m. ET at the Encore Boston Harbor. A live webcast
- 2y agoIRWDIronwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoIRWDIronwood Pharmaceuticals Reports Second Quarter 2024 ResultsBusiness Wire– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to
- 2y agoIRWDIronwood Pharmaceuticals to Host Second Quarter 2024 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested
- 2y agoIMTXIRWDALDRVECTMemo Therapeutics AG appoints Paul Carter as ChairpersonGlobeNewswirePRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market
- 2y agoIRWDIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at
- 2y agoIRWDIronwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)Business Wire– New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24
- 2y agoIRWDIronwood Pharmaceuticals, Inc. (IRWD) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoIRWDIronwood Pharmaceuticals Reports First Quarter 2024 ResultsBusiness Wire– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF) – – Reported positive results from Phase II
- 2y agoIRWDIronwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences ConferenceBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 10:00 a.m. ET at the New York
- 2y agoIRWDIronwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024Business Wire– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure (SBS-IF) accepted as late-breaker oral presentation on May 21 at 10:30 am ET – – Findings from the STARS Nutrition Study in
- 2y agoIRWDIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update CallBusiness WireIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in
- 2y agoIRWDIronwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)Business Wire– First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD – – Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study's
- 2y agoIRWDIronwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)Business Wire– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations – – Apraglutide also showed
- 2y agoIRWDIronwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice ConferenceBusiness Wire– Apraglutide nutritional data from STARS Nutrition Phase 2 study in adult patients who have short bowel syndrome with intestinal failure and colon-in-continuity will be highlighted in an oral presentation – –